Big drug companies might not be so defensive anymore. Here’s why.
CNBC Pharmaceuticals Reporter Mike Huckman joins the panel for this conversation. Following is a summary of the points he made.
Why Big Pharma might not be a defensive play....
1. Patent expiration cycle -- billions of dollars worth of brand-name drugs go off patent over the next few years.
2. Regulatory risks -- Chantix, Avandia, anemia drugs and others under scrutiny